HCC

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma (HCC).

In a 2015, retrospective single-center study, patients with advanced HCC received systemic therapy with sorafenib combined with transarterial chemoembolization (TACE), and outcomes were compared between elderly (>70 years) and nonelderly (<70 years) patients.

Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.

New agents that focus on the duplication of HCV are poised to majorly impact the prevention and recurrence of HCC, as well as show the ability to reverse liver fibrosis and cirrhosis in the treatment of patients with end-stage HCC.

The ASCO Annual Meeting is always packed with the latest and greatest advances in the field of oncology, and this year was no exception! The 2015 meeting had posted record-breaking numbers for abstract submissions and attendance, with over 37,000 individuals crowding the halls of the McCormick Place in Chicago.

Treatment with ramucirumab did not demonstrate a statistically significant improvement in overall survival compared with placebo for patients with hepatocellular carcinoma who had received prior treatment with sorafenib.

Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma